Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates

Robert J. McDonald, Deborah Levine, Jeffrey Weinreb, Emanuel Kanal, Matthew S. Davenport, James H. Ellis, Paula M. Jacobs, Robert E. Lenkinski, Kenneth R. Maravilla, Martin R. Prince, Howard A. Rowley, Michael F. Tweedle, Herbert Y. Kressel

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Gadolinium-based contrast agents (GBCAs) have revolutionized MRI, enabling physicians to obtain crucial life-saving medical information that often cannot be obtained with other imaging modalities. Since initial approval in 1988, over 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile; however, recent information has raised new concerns over the safety of GBCAs. Mounting evidence has shown there is long-term retention of gadolinium in human tissues. Further, a small subset of patients have attributed a constellation of symptoms to GBCA exposure, although the association of these symptoms with GBCA administration or gadolinium retention has not been proven by scientific investigation. Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium retention are unknown. The mechanism and chemical forms of gadolinium retention, as well as the biologic activity and clinical importance of these retained gadolinium species, remain poorly understood and underscore the need for additional research. In February 2018, an international meeting was held in Bethesda, Md, at the National Institutes of Health to discuss the current literature and knowledge gaps about gadolinium retention, to prioritize future research initiatives to better understand this phenomenon, and to foster collaborative standardized studies. The greatest priorities are to determine (a) if gadolinium retention adversely affects the function of human tissues, (b) if retention is causally associated with short- or long-term clinical manifestations of disease, and (c) if vulnerable populations, such as children, are at greater risk for experiencing clinical disease. The purpose of the research roadmap is to highlight important information that is not known and to identify and prioritize needed research.

Original languageEnglish (US)
Pages (from-to)517-534
Number of pages18
JournalRadiology
Volume289
Issue number2
DOIs
StatePublished - Nov 1 2018

Fingerprint

Gadolinium
Education
Research
Contrast Media
Safety
National Institutes of Health (U.S.)
Vulnerable Populations

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

McDonald, R. J., Levine, D., Weinreb, J., Kanal, E., Davenport, M. S., Ellis, J. H., ... Kressel, H. Y. (2018). Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology, 289(2), 517-534. https://doi.org/10.1148/radiol.2018181151

Gadolinium Retention : A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. / McDonald, Robert J.; Levine, Deborah; Weinreb, Jeffrey; Kanal, Emanuel; Davenport, Matthew S.; Ellis, James H.; Jacobs, Paula M.; Lenkinski, Robert E.; Maravilla, Kenneth R.; Prince, Martin R.; Rowley, Howard A.; Tweedle, Michael F.; Kressel, Herbert Y.

In: Radiology, Vol. 289, No. 2, 01.11.2018, p. 517-534.

Research output: Contribution to journalArticle

McDonald, RJ, Levine, D, Weinreb, J, Kanal, E, Davenport, MS, Ellis, JH, Jacobs, PM, Lenkinski, RE, Maravilla, KR, Prince, MR, Rowley, HA, Tweedle, MF & Kressel, HY 2018, 'Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates', Radiology, vol. 289, no. 2, pp. 517-534. https://doi.org/10.1148/radiol.2018181151
McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH et al. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology. 2018 Nov 1;289(2):517-534. https://doi.org/10.1148/radiol.2018181151
McDonald, Robert J. ; Levine, Deborah ; Weinreb, Jeffrey ; Kanal, Emanuel ; Davenport, Matthew S. ; Ellis, James H. ; Jacobs, Paula M. ; Lenkinski, Robert E. ; Maravilla, Kenneth R. ; Prince, Martin R. ; Rowley, Howard A. ; Tweedle, Michael F. ; Kressel, Herbert Y. / Gadolinium Retention : A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. In: Radiology. 2018 ; Vol. 289, No. 2. pp. 517-534.
@article{857c811eceef4aa79aba4304112f68ba,
title = "Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates",
abstract = "Gadolinium-based contrast agents (GBCAs) have revolutionized MRI, enabling physicians to obtain crucial life-saving medical information that often cannot be obtained with other imaging modalities. Since initial approval in 1988, over 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile; however, recent information has raised new concerns over the safety of GBCAs. Mounting evidence has shown there is long-term retention of gadolinium in human tissues. Further, a small subset of patients have attributed a constellation of symptoms to GBCA exposure, although the association of these symptoms with GBCA administration or gadolinium retention has not been proven by scientific investigation. Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium retention are unknown. The mechanism and chemical forms of gadolinium retention, as well as the biologic activity and clinical importance of these retained gadolinium species, remain poorly understood and underscore the need for additional research. In February 2018, an international meeting was held in Bethesda, Md, at the National Institutes of Health to discuss the current literature and knowledge gaps about gadolinium retention, to prioritize future research initiatives to better understand this phenomenon, and to foster collaborative standardized studies. The greatest priorities are to determine (a) if gadolinium retention adversely affects the function of human tissues, (b) if retention is causally associated with short- or long-term clinical manifestations of disease, and (c) if vulnerable populations, such as children, are at greater risk for experiencing clinical disease. The purpose of the research roadmap is to highlight important information that is not known and to identify and prioritize needed research.",
author = "McDonald, {Robert J.} and Deborah Levine and Jeffrey Weinreb and Emanuel Kanal and Davenport, {Matthew S.} and Ellis, {James H.} and Jacobs, {Paula M.} and Lenkinski, {Robert E.} and Maravilla, {Kenneth R.} and Prince, {Martin R.} and Rowley, {Howard A.} and Tweedle, {Michael F.} and Kressel, {Herbert Y.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1148/radiol.2018181151",
language = "English (US)",
volume = "289",
pages = "517--534",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - Gadolinium Retention

T2 - A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates

AU - McDonald, Robert J.

AU - Levine, Deborah

AU - Weinreb, Jeffrey

AU - Kanal, Emanuel

AU - Davenport, Matthew S.

AU - Ellis, James H.

AU - Jacobs, Paula M.

AU - Lenkinski, Robert E.

AU - Maravilla, Kenneth R.

AU - Prince, Martin R.

AU - Rowley, Howard A.

AU - Tweedle, Michael F.

AU - Kressel, Herbert Y.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Gadolinium-based contrast agents (GBCAs) have revolutionized MRI, enabling physicians to obtain crucial life-saving medical information that often cannot be obtained with other imaging modalities. Since initial approval in 1988, over 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile; however, recent information has raised new concerns over the safety of GBCAs. Mounting evidence has shown there is long-term retention of gadolinium in human tissues. Further, a small subset of patients have attributed a constellation of symptoms to GBCA exposure, although the association of these symptoms with GBCA administration or gadolinium retention has not been proven by scientific investigation. Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium retention are unknown. The mechanism and chemical forms of gadolinium retention, as well as the biologic activity and clinical importance of these retained gadolinium species, remain poorly understood and underscore the need for additional research. In February 2018, an international meeting was held in Bethesda, Md, at the National Institutes of Health to discuss the current literature and knowledge gaps about gadolinium retention, to prioritize future research initiatives to better understand this phenomenon, and to foster collaborative standardized studies. The greatest priorities are to determine (a) if gadolinium retention adversely affects the function of human tissues, (b) if retention is causally associated with short- or long-term clinical manifestations of disease, and (c) if vulnerable populations, such as children, are at greater risk for experiencing clinical disease. The purpose of the research roadmap is to highlight important information that is not known and to identify and prioritize needed research.

AB - Gadolinium-based contrast agents (GBCAs) have revolutionized MRI, enabling physicians to obtain crucial life-saving medical information that often cannot be obtained with other imaging modalities. Since initial approval in 1988, over 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile; however, recent information has raised new concerns over the safety of GBCAs. Mounting evidence has shown there is long-term retention of gadolinium in human tissues. Further, a small subset of patients have attributed a constellation of symptoms to GBCA exposure, although the association of these symptoms with GBCA administration or gadolinium retention has not been proven by scientific investigation. Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium retention are unknown. The mechanism and chemical forms of gadolinium retention, as well as the biologic activity and clinical importance of these retained gadolinium species, remain poorly understood and underscore the need for additional research. In February 2018, an international meeting was held in Bethesda, Md, at the National Institutes of Health to discuss the current literature and knowledge gaps about gadolinium retention, to prioritize future research initiatives to better understand this phenomenon, and to foster collaborative standardized studies. The greatest priorities are to determine (a) if gadolinium retention adversely affects the function of human tissues, (b) if retention is causally associated with short- or long-term clinical manifestations of disease, and (c) if vulnerable populations, such as children, are at greater risk for experiencing clinical disease. The purpose of the research roadmap is to highlight important information that is not known and to identify and prioritize needed research.

UR - http://www.scopus.com/inward/record.url?scp=85055072120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055072120&partnerID=8YFLogxK

U2 - 10.1148/radiol.2018181151

DO - 10.1148/radiol.2018181151

M3 - Article

C2 - 30204075

AN - SCOPUS:85055072120

VL - 289

SP - 517

EP - 534

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -